Upsher-Smith has expanded its fluoxetine product family with the launch of fluoxetine oral solution, 20 mg/5 ml.
Upsher-Smith's product, which is an antidepressant, is a generic of Eli Lilly’s Prozac oral solution. That product has been discontinued, Upsher-Smith said.
The fluoxetine oral solution market had a market value of approximately $14.2 million for the 12 months ending November 2022, according to IQVIA.
[Read more: Upsher-Smith extends generic Haldol line]
“We are very excited to lead this calendar year off with the launch of fluoxetine oral solution,” said Rich Fisher, president and chief operating officer of Upsher-Smith. “Upsher-Smith has many exciting things in store for 2023 including the opening of our world-class manufacturing facility in Maple Grove, Minn., and a rich pipeline of high-quality generic products, positioning the company for both near-term and future growth.”